Incorvaia Cristoforo, Gritti Bruna, Martignago Irene, Riario-Sforza Gian Galeazzo, Ridolo Erminia
Cardiologia/Pneumologia Riabilitativa, ASST Gaetano Pini/CTO, Milano, Italia.
Dipartimento di Medicina Clinica e Sperimentale, Università di Parma, Italia.
Ig Sanita Pubbl. 2016 Nov-Dec;72(6):583-588.
A large number of studies, evaluated by several meta-analyses, indicate that patients with chronic obstructive pulmonary disease (COPD) treated with inhaled corticosteroids have a significantly increased risk of pneumonia which, however, is not associated with a corresponding increase in mortality. The increased risk seems to be exclusive of COPD, since meta-analyses involving patients with asthma treated with inhaled corticosteroids did not show a risk of pneumonia higher than that of the general population. Possible interventions to reduce this risk are to improve adherence to guidelines for prescribing inhaled corticosteroids in COPD (often used even in mild to moderate disease, for which they are not indicated), and using lower doses.
多项研究经多项荟萃分析评估表明,接受吸入性糖皮质激素治疗的慢性阻塞性肺疾病(COPD)患者患肺炎的风险显著增加,然而,这与死亡率的相应增加并无关联。这种风险增加似乎仅与慢性阻塞性肺疾病有关,因为涉及接受吸入性糖皮质激素治疗的哮喘患者的荟萃分析并未显示其患肺炎的风险高于普通人群。降低这种风险的可能干预措施包括提高对慢性阻塞性肺疾病吸入性糖皮质激素处方指南的依从性(即使在轻度至中度疾病中也经常使用,而该指南并不适用于此类疾病),以及使用更低剂量。